We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Total Nitrosamine Testing for Pharmaceuticals
Product News

Total Nitrosamine Testing for Pharmaceuticals

Total Nitrosamine Testing for Pharmaceuticals
Product News

Total Nitrosamine Testing for Pharmaceuticals


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Total Nitrosamine Testing for Pharmaceuticals"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ellutia will present its total nitrosamines pre-screening solution for pharmaceuticals at Analytica. As the European Medicines Agency (EMA) risk assessment deadline takes hold, Ellutia’s test is designed to deliver a clear pass/fail result for apparent total nitrosamine content (ATNC) in minutes, allowing samples to be immediately cleared for processing or sent for further testing.

From April 2020, all marketing authorization holders of medicines containing chemically synthesized active pharmaceutical ingredients (APIs) must conduct a risk assessment to evaluate the possibility of nitrosamines being present.

Any sample showing an ATNC below the World Health Organisation (WHO)’s specified interim limit cannot possibly contain any one nitrosamine above the total level, and so can be deemed safe.

The Ellutia ATNC test is based on the 800 Series Thermal Energy Analyser (TEA) interfaced to a unique chemical stripping system. It allows pharmaceutical manufacturers to meet the requirements of the EMA risk assessment without needing to outsource testing of raw materials or of product at different stages of manufacturing. 

Andrew James, marketing director at Ellutia, said: “Measuring apparent total nitrosamine content (ATNC) provides a benchmark of the nitrosamine volume in a product. Rather than embark on a lengthy analytical process to deliver detailed and speciated results in the first instance, the ATNC method screens only for the total nitrosamine content, both volatile and non-volatile compounds, and returns an analysis with a single clear peak. If this peak falls under the interim allowable daily intakes set by the World Health Organisation (WHO) for specific species of nitrosamines, the total nitrosamine content is permitted and the product is safe. 

“In contrast, any sample found to contain an ATNC outside the safe level can be red flagged and sent for further analysis by a TEA interfaced to a GC or HPLC to individually identify the species and quantify the presence of nitrosamines such as NDMA.

“The risk assessment requirement from the European medicines agency means that pharmaceutical manufacturers need to take a serious look at potential nitrosamine contamination in their product lines. In America, too, the US Food and Drug Administration (FDA) has also already acted to call in various drugs known as ARBs for testing.

The TEA has become the industry go-to for nitrosamine testing in GMP manufacturing environments such as food safety and materials testing. Coupled with Ellutia’s chemical stripping system, the instrument is seeing take up in pharmaceuticals testing."

Advertisement